PTD-DBM is a cell‑penetrating peptide that blocks the CXXC5‑Dishevelled interaction to activate Wnt/β‑catenin signaling, and the community primarily experiments with it for hair follicle regeneration. Users typically administer 2 mg per day, with timing and cycling left to individual preference because most reports omit a schedule. The only clear limitation is that it has no FDA‑approved indication and all human use is off‑label or compounded; no side effects have been consistently reported, and injection‑site reactions have not emerged as a recurring issue.
Data last updated
Measured on 2 of 6 axes
Evidence shape
No registered clinical trials extracted for PTD-DBM yet.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Symptom-relevant clinical or community evidence has not been captured for this peptide yet.
price offers can be sorted by column
How PTD-DBM is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
The only community anecdote cites a 2 mg subcutaneous dose of PTD‑DBM, without specifying how often it is taken or any cycling regimen.